MedRhythms has announced the initiation of a multi-site clinical trial, in collaboration with Boston University, of its pipeline asset MR-005 in Parkinson’s disease as well as the expansion of the company’s pipeline into aging with the development of its Aging Scientific Advisory Board.
[MedRhythms (PR Newswire, LLC)]
6807162
{6807162:nan}
apa
50
1
161147
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
